SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 2
    Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002; 61 Suppl: ii846.
  • 3
    Forslind K, Boonen A, Albertsson K, Hafstrom I, Svensson B. Hand bone loss measured by digital x-ray radiogrammetry is a predictor of joint damage in early rheumatoid arthritis. Scand J Rheumatol 2009; 38: 4318.
  • 4
    Hoff M, Haugeberg G, Kvien TK. Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Res Ther 2007; 9: R81.
  • 5
    Stewart A, Mackenzie LM, Black AJ, Reid DM. Predicting erosive disease in rheumatoid arthritis: a longitudinal study of changes in bone density using digital x-ray radiogrammetry. A pilot study. Rheumatology (Oxford) 2004; 43: 15614.
  • 6
    Deodhar AA, Brabyn J, Pande I, Scott DL, Woolf AD. Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis 2003; 62: 76770.
  • 7
    Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, et al. Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 2006; 65: 73640.
  • 8
    Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 12329.
  • 9
    Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233: 30112.
  • 10
    Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008; 35: 5159.
  • 11
    Altomonte L, Zoli A, Mirone L, Scolieri P, Magaro M. Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis: correlation with disease activity. Clin Rheumatol 1992; 11: 2025.
  • 12
    Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 104754.
  • 13
    Espersen GT, Vestergaard M, Ernst E, Grunnet N. Tumour necrosis factor α and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity. Clin Rheumatol 1991; 10: 3746.
  • 14
    Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, et al. Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 2008; 59: 91120.
  • 15
    Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 2324.
  • 16
    Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritis. Clin Rheumatol 2006; 25: 44852.
  • 17
    Sugiyama E, Kuroda A, Hori F, Hori T, Taki H, Arai N, et al. Serum interleukin-6 level is a sensitive parameter of disease activity in rheumatoid arthritis. J Clin Rheumatol 1995; 1: 938.
  • 18
    Yue C, You X, Zhao L, Wang H, Tang F, Zhang F, et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2010; 30: 15537.
  • 19
    Schett G, Saag KG, Bijlsma JW. From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis 2010; 69: 14159.
  • 20
    Book C, Karlsson M, Akesson K, Jacobsson L. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. Scand J Rheumatol 2008; 37: 24854.
  • 21
    Jensen T, Klarlund M, Hansen M, Jensen KE, Podenphant J, Hansen TM, et al. Bone loss in unclassified polyarthritis and early rheumatoid arthritis is better detected by digital x ray radiogrammetry than dual x ray absorptiometry: relationship with disease activity and radiographic outcome. Ann Rheum Dis 2004; 63: 1522.
  • 22
    Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006; 24 Suppl: S7782.
  • 23
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 338190.
  • 24
    Van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 91421.
  • 25
    Rosholm A, Hyldstrup L, Backsgaard L, Grunkin M, Thodberg HH. Estimation of bone mineral density by digital x-ray radiogrammetry: theoretical background and clinical testing. Osteoporos Int 2001; 12: 9619.
  • 26
    Hoff M, Dhainaut A, Kvien TK, Forslind K, Kalvesten J, Haugeberg G. Short-time in vitro and in vivo precision of direct digital x-ray radiogrammetry. J Clin Densitom 2009; 12: 1721.
  • 27
    Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 2613.
  • 28
    Zhang Y, Yu K. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 16901.
  • 29
    Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 150812.
  • 30
    Bottcher J, Pfeil A, Rosholm A, Petrovitch A, Seidl BE, Malich A, et al. Digital x-ray radiogrammetry combined with semiautomated analysis of joint space widths as a new diagnostic approach in rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Rheum 2005; 52: 38509.
  • 31
    Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis 2008; 67: 8238.
  • 32
    Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68: 3306.
  • 33
    Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 2004; 63: 157680.
  • 34
    Ainola MM, Mandelin JA, Liljestrom MP, Li TF, Hukkanen MV, Konttinen YT. Pannus invasion and cartilage degradation in rheumatoid arthritis: involvement of MMP-3 and interleukin-1β. Clin Exp Rheumatol 2005; 23: 64450.
  • 35
    O'Gradaigh D, Ireland D, Bord S, Compston JE. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor α, interleukin 1, and receptor activator of nuclear factor κB ligand (RANKL) regulate osteoclasts. Ann Rheum Dis 2004; 63: 3549.
  • 36
    Schett G. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity 2008; 41: 2249.
  • 37
    Hafstrom I, Albertsson K, Boonen A, van der Heijde D, Landewe R, Svensson B. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009; 68: 50813.
  • 38
    Islander U, Jochems C, Lagerquist MK, Forsblad-d'Elia H, Carlsten H. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011; 335: 1429.
  • 39
    Forsblad-d'Elia H, Carlsten H. Hormone replacement therapy in postmenopausal women with rheumatoid arthritis stabilises bone mineral density by digital x-ray radiogrammetry in a randomised controlled trial [letter]. Ann Rheum Dis 2011; 70: 11678.
  • 40
    Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug–induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum 2006; 54: 376173.
  • 41
    Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum 2009; 60: 191522.
  • 42
    Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 2004; 50: 3642.
  • 43
    Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis 2007; 66: 35863.
  • 44
    Bansback N, Young A, Brennan A, Dixey J. A prognostic model for functional outcome in early rheumatoid arthritis. J Rheumatol 2006; 33: 150310.
  • 45
    Morel J, Combe B. How to predict prognosis in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19: 13746.
  • 46
    Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995; 22: 10559.
  • 47
    Kirchgatterer A, Aschl G, Knoflach P. Steroid-induced osteoporosis: pathogenesis and therapeutic consequences. Acta Med Austriaca 2000; 27: 236. In German.
  • 48
    Reid IR. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol (Oxf) 1989; 30: 83103.
  • 49
    Bottcher J, Pfeil A, Mentzel H, Kramer A, Schafer ML, Lehmann G, et al. Peripheral bone status in rheumatoid arthritis evaluated by digital x-ray radiogrammetry and compared with multisite quantitative ultrasound. Calcif Tissue Int 2006; 78: 2534.
  • 50
    Bottcher J, Pfeil A, Rosholm A, Malich A, Petrovitch A, Heinrich B, et al. Influence of image-capturing parameters on digital x-ray radiogrammetry. J Clin Densitom 2005; 8: 8794.